The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Gullimex trekt investeerder Holland Capital aan voor verdere groei
Investeringsmaatschappij Holland Capital investeert in Gullimex, een sterke speler op het gebied van meet-, kwaliteit- en controleoplossingen in de food en medical sector. De investering van Holland Capital biedt Gullimex de mogelijkheid de gestelde groeiambities te realiseren.
Our portfolio company Sirius Medical is partnering with Mammotome
Our portfolio company Sirius Medical, the innovator of Surgical Marker Navigation and Mammotome, a globally recognized leader in breast care, are proud to announce an exclusive distribution agreement for the United States and Germany.
Ons portfoliobedrijf Sirius Medical en Mammotome gaan samenwerking aan
Ons portfoliobedrijf Sirius Medical, pionier op het gebied van Surgical Marker Navigation, en Mammotome, een wereldwijd erkende leider in borstkankerzorg, zijn trots om een exclusieve distributieovereenkomst voor de Verenigde Staten en Duitsland aan te kondigen.
Our portfolio company Sirius Medical secures growth funding from new and existing investors
Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day.
Sirius Medical haalt groeifinanciering op bij nieuwe en bestaande investeerders
Ons portfolio bedrijf Sirius Medical, een toonaangevend medisch-technologiebedrijf en marktleider in onco-chirurgische marker-navigatie, heeft een financiering van € 10 miljoen euro opgehaald op Wereldkankerdag.
Beyonder is de nieuwe naam van House of Clouds
House of Clouds heeft een belangrijke stap gezet in haar groeiambities en gaat vanaf vandaag verder onder de naam Beyonder. Tijdens een feestelijke bijeenkomst in het Eindhovense Natlab onthulde CEO Sander Dekker de nieuwe naam en merkidentiteit, samen met alle collega’s.
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl


